NCT02955420View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

74

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

May 31, 2018

Conditions

Healthy Volunteers

Interventions

DRUG

BC 007

DRUG

NaCl 0.9 %

Trial Locations (1)

14050

PAREXEL International GmbH, Early Phase Clinical Unit Berlin, Berlin

Sponsors

Lead Sponsor

Berlin Cures GmbH

All Listed Sponsors

lead

Berlin Cures GmbH

INDUSTRY